Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

478 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
The administration route of tumor-antigen-specific T-helper cells differentially modulates the tumor microenvironment and senescence.
Griessinger CM, Schmid AM, Sonanini D, Schörg BF, Jarboui MA, Bukala D, Mucha N, Fehrenbacher B, Steinhilber J, Martella M, Kohlhofer U, Schaller M, Zender L, Rammensee HG, Quintanilla-Martinez L, Röcken M, Kneilling M, Pichler BJ. Griessinger CM, et al. Among authors: rammensee hg. Carcinogenesis. 2019 Apr 29;40(2):289-302. doi: 10.1093/carcin/bgy161. Carcinogenesis. 2019. PMID: 30753335
Analysis of tumor antigen-specific T cells and antibodies in cancer patients treated with radiofrequency ablation.
Widenmeyer M, Shebzukhov Y, Haen SP, Schmidt D, Clasen S, Boss A, Kuprash DV, Nedospasov SA, Stenzl A, Aebert H, Wernet D, Stevanović S, Pereira PL, Rammensee HG, Gouttefangeas C. Widenmeyer M, et al. Among authors: rammensee hg. Int J Cancer. 2011 Jun 1;128(11):2653-62. doi: 10.1002/ijc.25601. Epub 2010 Oct 8. Int J Cancer. 2011. PMID: 20715115
Cutaneous innate immune sensing of Toll-like receptor 2-6 ligands suppresses T cell immunity by inducing myeloid-derived suppressor cells.
Skabytska Y, Wölbing F, Günther C, Köberle M, Kaesler S, Chen KM, Guenova E, Demircioglu D, Kempf WE, Volz T, Rammensee HG, Schaller M, Röcken M, Götz F, Biedermann T. Skabytska Y, et al. Among authors: rammensee hg. Immunity. 2014 Nov 20;41(5):762-75. doi: 10.1016/j.immuni.2014.10.009. Epub 2014 Nov 13. Immunity. 2014. PMID: 25456159 Free article.
64Cu antibody-targeting of the T-cell receptor and subsequent internalization enables in vivo tracking of lymphocytes by PET.
Griessinger CM, Maurer A, Kesenheimer C, Kehlbach R, Reischl G, Ehrlichmann W, Bukala D, Harant M, Cay F, Brück J, Nordin R, Kohlhofer U, Rammensee HG, Quintanilla-Martinez L, Schaller M, Röcken M, Pichler BJ, Kneilling M. Griessinger CM, et al. Among authors: rammensee hg. Proc Natl Acad Sci U S A. 2015 Jan 27;112(4):1161-6. doi: 10.1073/pnas.1418391112. Epub 2015 Jan 13. Proc Natl Acad Sci U S A. 2015. PMID: 25587131 Free PMC article.
NFAT2 is a critical regulator of the anergic phenotype in chronic lymphocytic leukaemia.
Märklin M, Heitmann JS, Fuchs AR, Truckenmüller FM, Gutknecht M, Bugl S, Saur SJ, Lazarus J, Kohlhofer U, Quintanilla-Martinez L, Rammensee HG, Salih HR, Kopp HG, Haap M, Kirschniak A, Kanz L, Rao A, Wirths S, Müller MR. Märklin M, et al. Among authors: rammensee hg. Nat Commun. 2017 Oct 2;8(1):755. doi: 10.1038/s41467-017-00830-y. Nat Commun. 2017. PMID: 28970470 Free PMC article.
First case report of malignant peritoneal mesothelioma and oral verrucous carcinoma in a patient with a germline PTEN mutation: a combination of extremely rare diseases with probable further implications.
Löffler MW, Steinhilber J, Hilke FJ, Haen SP, Bösmüller H, Montes-Mojarro IA, Bonzheim I, Stäbler A, Faust U, Grasshoff U, Königsrainer I, Rammensee HG, Kanz L, Königsrainer A, Beckert S, Riess O, Schroeder C. Löffler MW, et al. Among authors: rammensee hg. BMC Med Genet. 2018 Aug 15;19(1):144. doi: 10.1186/s12881-018-0651-4. BMC Med Genet. 2018. PMID: 30111295 Free PMC article.
Targeting tumor-resident mast cells for effective anti-melanoma immune responses.
Kaesler S, Wölbing F, Kempf WE, Skabytska Y, Köberle M, Volz T, Sinnberg T, Amaral T, Möckel S, Yazdi A, Metzler G, Schaller M, Hartmann K, Weide B, Garbe C, Rammensee HG, Röcken M, Biedermann T. Kaesler S, et al. Among authors: rammensee hg. JCI Insight. 2019 Oct 3;4(19):e125057. doi: 10.1172/jci.insight.125057. JCI Insight. 2019. PMID: 31578309 Free PMC article.
A new synthetic toll-like receptor 1/2 ligand is an efficient adjuvant for peptide vaccination in a human volunteer.
Rammensee HG, Wiesmüller KH, Chandran PA, Zelba H, Rusch E, Gouttefangeas C, Kowalewski DJ, Di Marco M, Haen SP, Walz JS, Gloria YC, Bödder J, Schertel JM, Tunger A, Müller L, Kießler M, Wehner R, Schmitz M, Jakobi M, Schneiderhan-Marra N, Klein R, Laske K, Artzner K, Backert L, Schuster H, Schwenck J, Weber ANR, Pichler BJ, Kneilling M, la Fougère C, Forchhammer S, Metzler G, Bauer J, Weide B, Schippert W, Stevanović S, Löffler MW. Rammensee HG, et al. J Immunother Cancer. 2019 Nov 15;7(1):307. doi: 10.1186/s40425-019-0796-5. J Immunother Cancer. 2019. PMID: 31730025 Free PMC article.
An IgG-based bispecific antibody for improved dual targeting in PSMA-positive cancer.
Zekri L, Vogt F, Osburg L, Müller S, Kauer J, Manz T, Pflügler M, Maurer A, Heitmann JS, Hagelstein I, Märklin M, Hörner S, Todenhöfer T, Calaminus C, Stenzl A, Pichler B, la Fougère C, Schneider MA, Rammensee HG, Zender L, Sipos B, Salih HR, Jung G. Zekri L, et al. Among authors: rammensee hg. EMBO Mol Med. 2021 Feb 5;13(2):e11902. doi: 10.15252/emmm.201911902. Epub 2020 Dec 29. EMBO Mol Med. 2021. PMID: 33372710 Free PMC article.
478 results